2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3101 Meld-sodium predicts bleeding in patients with cirrhosis

Amber Afzal, MD, MSCI, Suhong Luo2, Amir Mahmoud, MBBCh, MSc3, Kristen Marie Sanfilippo, MD, MPHS4
1 Washington University In Saint Louis, Saint Louis, Missouri, United States
2 Washington University In Saint Louis, Saint Louis, Missouri, United States
3 Washington University In Saint Louis, Saint Louis, Missouri, United States
4 Washington University In Saint Louis, Saint Louis, Missouri, United States, Washington University In Saint Louis, Saint Louis, Missouri, United States

Background: Patients with cirrhosis are 1.5-fold more likely to develop atrial fibrillation (AF) than those without liver disease, making anticoagulation a frequent therapeutic consideration. However, the increased risk of major bleeding including hemorrhagic stroke in cirrhosis underscores the need for individualized bleeding risk assessment before treatment decisions {Proietti, 2021, Riahi 2022}. The Model for End-stage Liver Disease Sodium (MELD-Na) score is widely used to assess liver disease severity, mortality risk, and transplant eligibility, but its ability to predict bleeding remains uncertain.

Aim: To evaluate the association between MELD-Na score and clinically significant bleeding in patients with cirrhosis and incident AF.

Methods: We conducted a retrospective cohort study of patients with cirrhosis and incident AF using Veterans Health Administration data. Cirrhosis and incident AF, defined as 'new' AF diagnosis after cirrhosis, were identified using 1 inpatient or 2 outpatient validated ICD-9/10 codes with >/=90% positive predictive value. MELD-Na was calculated for the study population using laboratory values obtained within one year before AF diagnosis. The primary outcome was clinically significant bleeding requiring hospitalization, identified using validated inpatient ICD-9/10 coding algorithms. Association between MELD-Na and bleeding was evaluated using multivariable Fine-Gray competing-risk regression accounting for death as a competing event and adjusting for prespecified confounders. Analyses were performed using SAS version 9.4. Two-sided P<0.05 was considered statistically significant.

Results: The study cohort included 7,852 patients with cirrhosis and incident AF diagnosed between 2010 and 2022. Median age was 67 years, 98% were male, and 17.2% were non-White. Most patients (80.3%) had a MELD-Na score > 10. During a median follow-up of 63 months, 11.6% patients experienced clinically significant bleeding (incidence rate 7.45 per 100 person-years).

A MELD-Na score >10 was independently associated with a 20% higher risk of clinically significant bleeding versus MELD-Na ≤10 (subdistribution hazard ratio 1.2, 95% CI 1.05-1.36). Additional predictors of bleeding included thrombocytopenia, fall risk, and alcoholic liver disease, whereas no significant association with bleeding was found for age, body mass index, race, uncontrolled hypertension, anemia, and anti thrombotic therapy.

Conclusions: MELD-Na independently predicts clinically significant bleeding in patients with cirrhosis and AF, extending its prognostic utility beyond mortality. MELD-Na may improve individualized assessment of bleeding when considering anticoagulation in this population.

Amber Afzal, MD, MSCI: No relevant conflicts of interest to declare.